Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label ceftazidime-avibactam plus metronidazole for complicated intra-abdominal infection in Japanese adults
jRCT2061210026Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ceftazidime + avibactam in Intra-abdominal infection (IAI) and sepsis, sponsored by Pfizer. Primary endpoint: Clinical cure at test of cure (primary). Started Oct 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Intra-abdominal infection (IAI)sepsis
Beyond the preview
Go deeper on jRCT2061210026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210026.